SOLUM COSMETIC acquires 35.3% of I-CURE for 21.2B KRW
솔루엠
248070
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=707
Risk-adjusted indicator based on 707 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Acquisition Amount: 21,200,000,668 KRW
- • Acquired Shares: 20,502,902 Shares
- • Post-acquisition Ownership: 35.3%
- • Acquisition Target's 2025 Revenue: 83,385M KRW
- • Acquisition Target's 2025 Net Income: -34,515M KRW
AI Analysis Summary
SOLUM CO., LTD.'s subsidiary, SOLUM COSMETIC CORP., decided to acquire 20,502,902 shares of I-CURE for 21.2 billion KRW, representing a 35.3% stake. The acquisition aims to strengthen competitiveness and create synergy with existing portfolios in the cosmetics manufacturing sector. I-CURE's 2025 revenue was 83.385 billion KRW, with a net loss of 34.515 billion KRW. The acquisition amount represents 1.7% of SOLUM's total assets. The transaction is subject to government approvals and other conditions, with an expected acquisition date of August 6, 2026.
How This Event Is Evaluated
M&A / Merger Evaluation
M&A events are evaluated by assessing deal size relative to company scale, strategic rationale, financing structure, and integration risk.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Deal size relative to market value
- Strategic fit and synergy potential
- Financing structure (cash, stock, debt)
- Regulatory and integration risk
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.